Exocobio, A Leader In Exosome Technology, Completes The Acquisition Of Benev, A Global Medical Aesthetic Brand

Jul 12, 2023•over 2 years ago

Acquiring Company

ExoCoBio

Acquired Company

BENEV Company

BiotechnologyMedicalBiotechnologyHealth CareManufacturing

Description

ExoCoBio, a global leader in exosome-based regenerative aesthetics, is pleased to announce that they have completed the acquisition of a majority ownership in BENEV, a global medical aesthetic company based in the U.S.

Company Information

Company

ExoCoBio

About

ExoCoBio, established in 2017, is the world's leader in exosome-based regenerative aesthetics and medicine. It is one of top 3 exosome biotech companies and commercialized ASCE+TM and ERCTM, the world's first and best exosome-based aesthetic products, which led to a new exosome skin booster industry since 2019.

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Exocobio, A Leader In Exosome Technology, Completes The Acquisition Of Benev, A Global Medical Aesthetic Brand

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

M&A Insights

Company Information